Eli Lilly is seeing early signs that its $2.3 billion acquisition of Cambridge-based Ajax Therapeutics was money well spent. Just two months after closing the deal, the pharmaceutical giant reported positive results from the first clinical trial of Ajax's lead blood cancer drug.
According to reporting by MSN, the experimental treatment showed signs of working in roughly 70% of patients in the early-stage trial — a striking early figure for a drug still in the first phases of human testing.
The Ajax acquisition was one of Lilly's biggest recent bets on a single drug candidate. Cambridge, Massachusetts has become a hub for early-stage biotech companies, and Ajax was among the startups attracting serious attention for its approach to targeting blood cancers.
Early-phase clinical trials are designed primarily to test safety, not effectiveness, so a 70% response rate at this stage is notable — though the drug still faces multiple additional trial phases before it could ever reach patients or win regulatory approval. Many drugs that show early promise ultimately fail in larger, more rigorous studies.
Still, the timing matters. Lilly is under pressure to build its pipeline beyond its blockbuster weight-loss and diabetes drugs, and a successful blood cancer candidate would meaningfully diversify its portfolio. Positive early data also helps justify the steep price tag to investors who questioned whether $2.3 billion for an early-stage asset was prudent.
The result matters because it shows how large pharmaceutical companies are racing to buy promising science before it matures — and that, at least in this case, the early gamble appears to be paying off.